Sugi Predict

Sugi Predict / Targets / LPAR6

LPAR6

Lysophosphatidic acid receptor 6 · P43657 · LPAR6 on Sugi Atlas →

19,855 patent compounds predicted against LPAR6, 14,058 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL258032 SCHEMBL258032 0.61 5/20
SCHEMBL258094 SCHEMBL258094 0.61 5/20
SCHEMBL258118 SCHEMBL258118 0.61 5/20
SCHEMBL258136 SCHEMBL258136 0.61 5/20
SCHEMBL258161 SCHEMBL258161 0.61 5/20
SCHEMBL496845 SCHEMBL496845 0.56 5/20
SCHEMBL370759 SCHEMBL370759 0.54 5/20
SCHEMBL40048 SCHEMBL40048 0.50 5/20
SCHEMBL303128 SCHEMBL303128 0.50 5/20
SCHEMBL482324 SCHEMBL482324 0.50 5/20
SCHEMBL21003 SCHEMBL21003 0.47 5/20
SCHEMBL501728 SCHEMBL501728 0.47 5/20
SCHEMBL608015 SCHEMBL608015 0.47 5/20
SCHEMBL88391 SCHEMBL88391 0.46 5/20
SCHEMBL570522 SCHEMBL570522 0.45 5/20
SCHEMBL226510 SCHEMBL226510 0.44 5/20
SCHEMBL757679 SCHEMBL757679 0.44 5/20
SCHEMBL649061 SCHEMBL649061 0.43 5/20
SCHEMBL753952 SCHEMBL753952 0.42 5/20
Zinc Ion Zinc Ion (SCHEMBL163340) 0.41 5/20

Clinical trials — most relevant to LPAR6 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Diet Rich in N-3 Polyunsaturated Fatty Acids in Renal Transplant Recipients PHASE4COMPLETED
Effect of Sarilumab on Atherosclerotic Disease Assessed by PET/CET in Patients With RA (SARIPET) PHASE4UNKNOWN
Effect of Evolocumab on Vascular Function PHASE4COMPLETED
PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke PHASE4NOT_YET_RECRUITING
Montelukast in Parkinson Disease PHASE2/PHASE3RECRUITING
Fish Oil and Aspirin With Type 2 Diabetes PHASE2COMPLETED
A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin PHASE2UNKNOWN
Assessment of Coronary Plaque Composition PHASE1COMPLETED
The dıagnostıc Value of Serum autotaxın Level ın Colorectal Cancer nanCOMPLETED
Longitudinal Study on Bacterial Production of LPC and LPA in Patients With Inflammatory Bowel Disease nanRECRUITING
Autotaxin as Abiomarker in Systemic Lupus Erythematosus Patients nanUNKNOWN
Evaluation of Plasma Sphingosine-1-Phosphate as A Diagnostic and Prognostic Biomarkers of Community-Acquired Pneumonia nanUNKNOWN
Dose-response Effect of Pine Nut Oil as a Dual FFA1 and FFA4 Agonist on Glucose Tolerance in Healthy Humans. nanCOMPLETED
Evaluation of Cascade Screening for Elevated Lipoprotein(a) nanACTIVE_NOT_RECRUITING
Development of Therapeutic Approaches Modulating Molecular Targets Implicated on Cancer Stem Cell-related Aggressiveness nanUNKNOWN
Markers of Cardiovascular Risk in Patients With Premature Coronary Artery Disease and Treatment nanUNKNOWN
In Vitro Demonstration of Direct Platelet-Related Effects of PCSK9 Enzyme nanNOT_YET_RECRUITING
Vulvodynia: Identification of Potential Relevant Biomarkers nanCOMPLETED
Physiopathology of Pulmonary Arterial Hypertension: Mechanistic Studies nanUNKNOWN
MaxSimil and Vitamin K2: Determining Their Bioavailability nanCOMPLETED
FFAR Agonist on Incretins, Insulin, Lipids and Inflammation nanCOMPLETED
Influence of Pelacarsen on Patients After Myocardial Infarction With High Lp(a) Values (PEMILA) nanWITHDRAWN
Autotaxin (ATX) as a Marker for Breast Cancer nanUNKNOWN
Prospective Monocentric Clinical-biological Database nanRECRUITING
Assessment of CXCL5 Level in SLE Patients and Its Correlation with Disease Activity nanNOT_YET_RECRUITING
LDL-Apheresis for FSGS CardioRenal Outcomes nanCOMPLETED
Sex Hormones and Blood PCSK9 Levels nanCOMPLETED
Effects of Ozanimod on Immune-mediated Mechanisms of Neurodegeneration in Multiple Sclerosis - a Preclinical Study nanUNKNOWN
Positron Emission Tomography (PET) to Study Brain Signaling nanCOMPLETED
Epidemiology of Atherosclerosis nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a LPAR6 binder may also engage these)

ProteinNameSimilarity
Q4G072 — 1.000 Q4G072 →
Q8BMC0 — 0.998 Q8BMC0 →
Q8BLG2 — 0.996 Q8BLG2 →
LPAR4 Lysophosphatidic acid receptor 4 0.992 landscape →
Q95N02 — 0.987 Q95N02 →
Q924T8 — 0.987 Q924T8 →
P32250 — 0.986 P32250 →
Q2NNR5 — 0.984 Q2NNR5 →
CYSLTR1 Cysteinyl leukotriene receptor 1 0.983 landscape →
Q9ESG6 — 0.983 Q9ESG6 →
D4A4Q2 — 0.983 D4A4Q2 →
Q99JA4 — 0.982 Q99JA4 →
Q3ZBK9 — 0.981 Q3ZBK9 →
Q8BG55 — 0.980 Q8BG55 →
Q8BFU7 — 0.979 Q8BFU7 →
O14626 — 0.979 O14626 →
Q3U507 — 0.979 Q3U507 →
Q3SX17 — 0.978 Q3SX17 →
Q80Z39 — 0.978 Q80Z39 →
P2RY14 P2Y purinoceptor 14 0.978 landscape →
P2RY10 Putative P2Y purinoceptor 10 0.978 landscape →
Q924T9 — 0.977 Q924T9 →
Q9CPV9 — 0.977 Q9CPV9 →
O35881 — 0.977 O35881 →
GPR174 Probable G-protein coupled receptor 174 0.977 landscape →
Q920A1 — 0.976 Q920A1 →
D4A7K7 — 0.976 D4A7K7 →
Q9EP66 — 0.975 Q9EP66 →
Q9XSD4 — 0.975 Q9XSD4 →
CYSLTR2 Cysteinyl leukotriene receptor 2 0.974 landscape →